Critical Comparison: Vivos Therapeutics (NASDAQ:VVOS) and Curaleaf (OTCMKTS:CURLF)

Curaleaf (OTCMKTS:CURLF) and Vivos Therapeutics (NASDAQ:VVOS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and target prices for Curaleaf and Vivos Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curaleaf	0	0	2	3	3.60
Vivos Therapeutics	1	1	2	0	2.25

Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 1,615.69%. Given Vivos Therapeutics’ higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than Curaleaf.

Profitability

This table compares Curaleaf and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curaleaf	-2.62%	-0.88%	-0.26%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

Insider and Institutional Ownership

0.0% of Curaleaf shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Curaleaf and Vivos Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curaleaf	$1.27 billion	1.93	-$231.07 million	($0.13)	-80.54
Vivos Therapeutics	$17.44 million	0.13	-$21.17 million	($1.90)	-0.09

Vivos Therapeutics has lower revenue, but higher earnings than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Curaleaf has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.04, meaning that its share price is 504% more volatile than the S&P 500.

Summary

Curaleaf beats Vivos Therapeutics on 8 of the 14 factors compared between the two stocks.

About Curaleaf

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.